Dr Laura Waters talks about CNS
Case Discussion: Dr Laura Waters talks ART and CNS side effects
DELSTRIGO®▼ (doravirine/3TC/TDF)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO®▼ (doravirine)
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PIFELTRO®▼ (doravirine) 100 mg film-coated tablet is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older, weighing at least 35 kg, infected with HIV-1, without past or present evidence of resistance to the NNRTI class.
DELSTRIGO®▼ (100 mg doravirine/300 mg lamivudine/300 mg tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil) is indicated for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine or tenofovir.
DELSTRIGO®▼ is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg, who are infected with HIV-1, without the past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
Please consult the SmPC for further information before making any prescribing decisions.
In this video Dr Laura Waters shares a case of a 61-year old man living with HIV, presenting with low mood and insomnia, and discusses key considerations for switching ART.
Please note that this is one individual and cases may vary.
Filming fully organised and funded by MSD, including speaker’s honoraria. Views of the speaker are their own and do not represent the opinions of MSD.
Abbreviations
3TC: lamivudine; ART: antiretroviral therapy; CNS: central nervous system; TDF: tenofovir disoproxil fumarate.
Reference
- Molina J M, Orkin C et al. Safety and efficacy of doravirine in treatment-naïve adults with HIV-1: 4 years of experience from the DRIVE‑FORWARD and DRIVE‑AHEAD clinical trials. Presented at 2021 European AIDS Conference (EACS), Virtual and London, UK, 27‑30 October 2021
Supporting documentation
DELSTRIGO®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
PIFELTRO®▼ Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
